Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Nephrol ; 84(2): 100-3, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25707456

RESUMEN

Renal vein thrombosis (RVT) is an uncommon condition in adults and may be caused by endothelial damage, stasis, or hypercoagulable states. RVT is commonly identified in patients with nephrotic syndrome or malignancy. We present the case of a 57-yearold man with no past medical history who presented with a 1-month history of abdominal pain, dysuria, and hematuria. Initial laboratory studies were consistent with acute kidney injury (AKI). Imaging revealed bladder distension, enlargement of the prostate, bilateral hydronephrosis, and left renal vein thrombosis extending into the inferior vena cava. His renal failure and presenting symptoms resolved with placement of a Foley catheter and ureteral stent. The patient was discharged on anticoagulation. Here, we report a rare case of RVT that appears to have occurred as a consequence of obstructive uropathy causing massive bladder distention resulting in compression of the renal vein.


Asunto(s)
Venas Renales/patología , Obstrucción Uretral/complicaciones , Obstrucción del Cuello de la Vejiga Urinaria/complicaciones , Trombosis de la Vena/etiología , Lesión Renal Aguda/etiología , Vena Femoral/patología , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Stents , Tomografía Computarizada por Rayos X/métodos , Cateterismo Urinario/instrumentación , Vena Cava Inferior/patología
2.
JAMA ; 310(23): 2523-32, 2013 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-24346989

RESUMEN

IMPORTANCE: Chronic periodontitis, a destructive inflammatory disorder of the supporting structures of the teeth, is prevalent in patients with diabetes. Limited evidence suggests that periodontal therapy may improve glycemic control. OBJECTIVE: To determine if nonsurgical periodontal treatment reduces levels of glycated hemoglobin (HbA1c) in persons with type 2 diabetes and moderate to advanced chronic periodontitis. DESIGN, SETTING, AND PARTICIPANTS: The Diabetes and Periodontal Therapy Trial (DPTT), a 6-month, single-masked, multicenter, randomized clinical trial. Participants had type 2 diabetes, were taking stable doses of medications, had HbA1c levels between 7% and less than 9%, and untreated chronic periodontitis. Five hundred fourteen participants were enrolled between November 2009 and March 2012 from diabetes and dental clinics and communities affiliated with 5 academic medical centers. INTERVENTIONS: The treatment group (n = 257) received scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months. The control group (n = 257) received no treatment for 6 months. MAIN OUTCOMES AND MEASURES: Difference in change in HbA1c level from baseline between groups at 6 months. Secondary outcomes included changes in probing pocket depths, clinical attachment loss, bleeding on probing, gingival index, fasting glucose level, and Homeostasis Model Assessment (HOMA2) score. RESULTS: Enrollment was stopped early because of futility. At 6 months, mean HbA1c levels in the periodontal therapy group increased 0.17% (SD, 1.0), compared with 0.11% (SD, 1.0) in the control group, with no significant difference between groups based on a linear regression model adjusting for clinical site (mean difference, -0.05% [95% CI, -0.23% to 0.12%]; P = .55). Periodontal measures improved in the treatment group compared with the control group at 6 months, with adjusted between-group differences of 0.28 mm (95% CI, 0.18 to 0.37) for probing depth, 0.25 mm (95% CI, 0.14 to 0.36) for clinical attachment loss, 13.1% (95% CI, 8.1% to 18.1%) for bleeding on probing, and 0.27 (95% CI, 0.17 to 0.37) for gingival index (P < .001 for all). CONCLUSIONS AND RELEVANCE: Nonsurgical periodontal therapy did not improve glycemic control in patients with type 2 diabetes and moderate to advanced chronic periodontitis. These findings do not support the use of nonsurgical periodontal treatment in patients with diabetes for the purpose of lowering levels of HbA1c. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00997178.


Asunto(s)
Periodontitis Crónica/terapia , Raspado Dental , Complicaciones de la Diabetes/terapia , Diabetes Mellitus Tipo 2/sangre , Hemoglobina Glucada/análisis , Aplanamiento de la Raíz , Anciano , Glucemia , Clorhexidina/administración & dosificación , Periodontitis Crónica/sangre , Periodontitis Crónica/complicaciones , Complicaciones de la Diabetes/sangre , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antisépticos Bucales/administración & dosificación , Método Simple Ciego , Resultado del Tratamiento
3.
J Emerg Med ; 32(2): 167-9, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17307626

RESUMEN

Bilateral adrenal hemorrhage resulting in acute adrenal insufficiency is a rare complication of anticoagulant therapy. We present the case of a patient who came to the Emergency Department with unsuspected adrenal insufficiency, followed by a second visit within 1 month with shock, to demonstrate the importance of early detection and treatment.


Asunto(s)
Enfermedades de las Glándulas Suprarrenales/complicaciones , Insuficiencia Suprarrenal/etiología , Anticoagulantes/efectos adversos , Hemorragia/complicaciones , Hipotensión/etiología , Warfarina/efectos adversos , Enfermedades de las Glándulas Suprarrenales/inducido químicamente , Anciano , Hemorragia/inducido químicamente , Humanos , Hipotensión/tratamiento farmacológico , Riñón/patología , Masculino
4.
SAGE Open Med ; 5: 2050312116682125, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28228947

RESUMEN

OBJECTIVES: Studies of social support in diabetes have focused on the effects of support on the person with type 2 diabetes. We explored diabetes prevention effects of a culturally tailored diabetes self-management intervention in individuals without diabetes who were supporters of intervention participants. METHODS: This is a secondary analysis of data from a randomized clinical trial that involved 256 Mexican Americans with diabetes. Each study participant designated a supporter-spouse, relative, friend-who attended intervention sessions and assisted participants in attaining effective diabetes self-management. Supporter's glycosylated hemoglobin (A1C) data were tracked for 1 year to determine diabetes conversion rates in supporters without diabetes at baseline. RESULTS: Fewer individuals in the intervention group (n = 9) converted to an A1C above the 7% threshold, compared to the 1-year wait-listed control group (n = 16). We found a statistically significant difference (p = .021) at 12 months in the number of individuals whose A1C was ⩽8%, with fewer supporters above threshold in the intervention group (reduction of 48%). Supporters in the intervention group with prediabetes, based on baseline A1C, experienced a slight reduction in A1C, while control group supporters with prediabetes experienced an increase. DISCUSSION: The results suggest that there are potential benefits for family members and other supporters of persons with diabetes who participated in diabetes self-management programs.

5.
Acad Med ; 92(6): 774-779, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28557941

RESUMEN

PROBLEM: To better prepare graduating medical students to transition to the professional responsibilities of residency, 10 medical schools are participating in an Association of American Medical Colleges pilot to evaluate the feasibility of explicitly teaching and assessing 13 Core Entrustable Professional Activities for Entering Residency. The authors focused on operationalizing the concept of entrustment as part of this process. APPROACH: Starting in 2014, the Entrustment Concept Group, with representatives from each of the pilot schools, guided the development of the structures and processes necessary for formal entrustment decisions associated with students' increased responsibilities at the start of residency. OUTCOMES: Guiding principles developed by the group recommend that formal, summative entrustment decisions in undergraduate medical education be made by a trained group, be based on longitudinal performance assessments from multiple assessors, and incorporate day-to-day entrustment judgments by workplace supervisors. Key to entrustment decisions is evidence that students know their limits (discernment), can be relied on to follow through (conscientiousness), and are forthcoming despite potential personal costs (truthfulness), in addition to having the requisite knowledge and skills. The group constructed a developmental framework for discernment, conscientiousness, and truthfulness to pilot a model for transparent entrustment decision making. NEXT STEPS: The pilot schools are studying a number of questions regarding the pathways to and decisions about entrustment. This work seeks to inform meaningful culture change in undergraduate medical education through a shared understanding of the assessment of trust and a shared trust in that assessment.


Asunto(s)
Competencia Clínica/normas , Educación de Pregrado en Medicina/organización & administración , Evaluación Educacional/normas , Internado y Residencia/organización & administración , Competencia Profesional/normas , Sociedades Médicas/normas , Adulto , Femenino , Humanos , Masculino , Proyectos Piloto , Evaluación de Programas y Proyectos de Salud , Estados Unidos , Adulto Joven
6.
Endocr Pract ; 11(4): 272-80, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16006300

RESUMEN

OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia. Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate. In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons. Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate. Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.


Asunto(s)
Carbonato de Calcio/envenenamiento , Hipercalcemia/inducido químicamente , Adulto , Calcitriol/sangre , Diuréticos/uso terapéutico , Femenino , Fluidoterapia , Furosemida/uso terapéutico , Humanos , Hipercalcemia/sangre , Hipercalcemia/diagnóstico , Hipercalcemia/terapia , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Proteína Relacionada con la Hormona Paratiroidea/sangre , Insuficiencia Renal/sangre , Insuficiencia Renal/terapia
7.
Diabetes Educ ; 39(6): 820-7, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24047926

RESUMEN

PURPOSE: The purpose of the study was to (1) characterize leptin in Mexican Americans with poorly controlled type 2 diabetes, (2) examine relationships among leptin and indicators of diabetes status (body mass index and A1C), and (3) explore the effects of a culturally tailored diabetes self-management education intervention on leptin. METHODS: In Starr County, an impoverished Texas-Mexico border community, 252 Mexican Americans with type 2 diabetes were recruited to test a diabetes self-management education intervention culturally tailored in terms of language, dietary recommendations, social emphasis, family participation, and incorporation of cultural health beliefs. Groups of 8 participants were randomized to experimental or wait-listed control conditions. Outcomes were measured at 3, 6, and 12 months; by 12 months, 109 had complete leptin data. RESULTS: Most participants were women and, on average, 55 years of age, diagnosed with diabetes for 8 years, obese, and in poor glycemic control. Three variables-body mass index, sex, A1C-explained 36% of the variance in baseline leptin; there were no intervention effects on leptin. Sex, time, and gender × time interaction effects on leptin were statistically significant; greater increases in leptin over time occurred in women compared to men. In women, fasting blood glucose changes from baseline to 12 months significantly predicted leptin changes from baseline to 12 months; in men, body mass index changes predicted leptin change. CONCLUSIONS: With increasing obesity rates, further research is warranted to determine if leptin is a useful intervention target in type 2 diabetes.


Asunto(s)
Glucemia/metabolismo , Servicios de Salud Comunitaria , Diabetes Mellitus Tipo 2/terapia , Hemoglobina Glucada/metabolismo , Leptina/sangre , Americanos Mexicanos , Autocuidado , Adulto , Índice de Masa Corporal , Servicios de Salud Comunitaria/organización & administración , Características Culturales , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/etnología , Diabetes Mellitus Tipo 2/prevención & control , Femenino , Conductas Relacionadas con la Salud/etnología , Promoción de la Salud/organización & administración , Humanos , Masculino , México , Persona de Mediana Edad , Educación del Paciente como Asunto/organización & administración , Autocuidado/estadística & datos numéricos , Texas
8.
Int Forum Allergy Rhinol ; 3(12): 953-7, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24124056

RESUMEN

BACKGROUND: Intranasal corticosteroid irrigations, especially budesonide, are used increasingly in the management of chronic rhinosinusitis. In post-endoscopic sinus surgery patients, irrigations may offer improved delivery at higher doses to the paranasal sinuses than intranasal spray preparations. Fluticasone propionate may have higher potency and lower systemic bioavailability than budesonide, but there is little data on its effects as an intranasal irrigation on the hypothalamic-pituitary-adrenal axis or on ocular findings. METHODS: Adult patients who had previously undergone bilateral endoscopic sinus surgery and had not taken systemic corticosteroids in the last 6 months were prospectively enrolled. Subjects irrigated with 3 mg of fluticasone propionate in 240 mL saline solution twice daily. Salivary cortisol, intraocular pressure, and the presence of posterior subcapsular cataracts were measured before drug administration and after 6 weeks of continuous use. RESULTS: Twenty-three subjects completed the study. No subjects had salivary cortisol levels below the normal range before or after therapy, and there was no statistical difference in mean salivary cortisol levels pretreatment and posttreatment (0.294 vs 0.392 µg/dL; p = 0.27). There was no clinical or statistical difference in mean intraocular pressure before or after therapy (13.3 vs 13.3 mmHg; p = 0.86). No subjects developed a posterior subcapsular cataract. CONCLUSION: Fluticasone propionate irrigations did not suppress salivary cortisol levels or result in ocular changes. Irrigation with fluticasone propionate 3 mg in 240 mL saline twice daily may be a safe alternative to other intranasal or systemic corticosteroid treatments for chronic rhinosinusitis patients.


Asunto(s)
Androstadienos/efectos adversos , Catarata/inducido químicamente , Presión Intraocular/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Rinitis/tratamiento farmacológico , Sinusitis/tratamiento farmacológico , Adulto , Anciano , Enfermedad Crónica , Femenino , Fluticasona , Humanos , Hidrocortisona/análisis , Masculino , Persona de Mediana Edad , Lavado Nasal (Proceso)/efectos adversos , Lavado Nasal (Proceso)/métodos , Estudios Prospectivos , Rinitis/cirugía , Saliva/química , Sinusitis/cirugía , Resultado del Tratamiento
9.
Chest ; 140(5): 1216-1222, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21816912

RESUMEN

BACKGROUND: There is a renewed interest in adrenal function during severe sepsis. Most studies have used total serum cortisol levels; however, only free serum cortisol is biologically active. The aim of this study was to determine the validity of salivary cortisol levels as a surrogate for free serum cortisol levels during septic shock. METHODS: Fifty-seven patients with septic shock were studied to determine the correlation between total serum cortisol and salivary cortisol to free serum cortisol levels. Thirty-eight patients were included in the salivary to free serum cortisol correlation. Salivary cortisol level was tested by enzyme immunoassay. Serum total cortisol, free cortisol, and cortisol-binding globulin (CBG) levels were determined by liquid chromatography-mass spectrometry, equilibrium analysis, and radioimmunoassay, respectively. RESULTS: The mean ± SD age was 56.6 ± 18.5 years. Fifty-seven percent were women. APACHE (Acute Physiology and Chronic Health Evaluation) II score median was 26, Simplified Acute Physiology Score II median was 61, and Sequential Organ Failure Assessment median was 13. The correlation between salivary and free serum cortisol levels was 0.79 (95% CI, 0.63-0.89; P < .0001). The correlation between free serum cortisol and total serum cortisol levels was 0.86 (95% CI, 0.78-0.92; P < .0001). The mean ± SD free serum cortisol level was 2.27 ± 1.64 µg/dL. The mean ± SD salivary cortisol level was 2.60 ± 2.69 µg/dL. The mean ± SD total serum cortisol level was 21.56 ± 8.71 µg/dL. The mean ± SD CBG level was 23.54 ± 8.33 mg/dL. CONCLUSIONS: Salivary cortisol level can be used as a surrogate of free serum cortisol level in patients with septic shock with very good correlation. Salivary cortisol testing is noninvasive, easy to perform, and can be conducted daily.


Asunto(s)
Biomarcadores/metabolismo , Hidrocortisona/metabolismo , Saliva/química , Choque Séptico/metabolismo , APACHE , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Proteínas Portadoras/sangre , Cromatografía Liquida , Femenino , Humanos , Hidrocortisona/sangre , Técnicas para Inmunoenzimas , Masculino , Espectrometría de Masas , Persona de Mediana Edad , Radioinmunoensayo , Análisis de Regresión
10.
Diabetes Care ; 32(7): 1250-5, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19564474

RESUMEN

OBJECTIVE: To evaluate the safety and efficacy of ingested human recombinant interferon-alpha (hrIFN-alpha) for preservation of beta-cell function in young patients with recent-onset type 1 diabetes. RESEARCH DESIGN AND METHODS: Subjects aged 3-25 years in whom type 1 diabetes was diagnosed within 6 weeks of enrollment were randomly assigned to receive ingested hrIFN-alpha at 5,000 or 30,000 units or placebo once daily for 1 year. The primary outcome was change in C-peptide secretion after a mixed meal. RESULTS: Individuals in the placebo group (n = 30) lost 56 +/- 29% of their C-peptide secretion from 0 to 12 months, expressed as area under the curve (AUC) in response to a mixed meal. In contrast, children treated with hrIFN-alpha lost 29 +/- 54 and 48 +/- 35% (for 5,000 [n = 27] and 30,000 units [n = 31], respectively, P = 0.028, ANOVA adjusted for age, baseline C-peptide AUC, and study site). Bonferroni post hoc analyses for placebo versus 5,000 units and placebo versus 30,000 units demonstrated that the overall trend was determined by the 5,000-unit treatment group. Adverse events occurred at similar rates in all treatment groups. CONCLUSIONS: Ingested hrIFN-alpha was safe at the doses used. Patients in the 5,000-unit hrIFN-alpha treatment group maintained more beta-cell function 1 year after study enrollment than individuals in the placebo group, whereas this effect was not observed in patients who received 30,000 units hrIFN-alpha. Further studies of low-dose ingested hrIFN-alpha in new-onset type 1 diabetes are needed to confirm this effect.


Asunto(s)
Péptido C/sangre , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Células Secretoras de Insulina/fisiología , Interferón-alfa/uso terapéutico , Administración Oral , Adolescente , Adulto , Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/efectos de los fármacos , Péptido C/metabolismo , Niño , Preescolar , Nefropatías Diabéticas/prevención & control , Método Doble Ciego , Ingestión de Alimentos/fisiología , Humanos , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/uso terapéutico , Células Secretoras de Insulina/efectos de los fármacos , Interferón-alfa/administración & dosificación , Placebos , Adulto Joven
12.
Clin Endocrinol (Oxf) ; 63(5): 566-76, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16268810

RESUMEN

OBJECTIVE: Milk-alkali syndrome, once a common cause of hypercalcaemia, is now considered rare. Our aim was to estimate the prevalence of milk-alkali syndrome among hypercalcaemic, non-end-stage renal disease (non-ESRD) inpatients of a University Hospital and identify patients' and syndrome characteristics. DESIGN AND PATIENTS: In this retrospective chart review study, we identified patients hospitalized with possible hypercalcaemia between November 1998 and October 2003 by a computer search of admission, discharge and consultation diagnoses. Patients with renal transplantation, stage 5 chronic kidney disease (CKD-5) and those admitted for parathyroidectomy were excluded. The remaining patients' charts were reviewed for confirmation of hypercalcaemia and identification of the cause. In patients with milk-alkali syndrome, additional historical, clinical, laboratory and imaging data were collected. RESULTS: We identified 125 patients with hypercalcaemia, 11 (8.8%) of whom had milk-alkali syndrome, 42 (33.6%) had malignancy and 37 (29.6%) hyperparathyroidism. Thirty-five patients had severe hypercalcaemia, defined as corrected serum calcium 3.5 mmol/l. Malignancy accounted for 13 of those patients (37.1%) and milk-alkali for nine (25.7%). Conditions prevalent among the milk-alkali inpatients were female gender, hypertension, chronic kidney disease, osteoporosis, upper gastrointestinal diseases, diuretic treatment and vitamin D derivative supplementation. Five of the patients with milk-alkali syndrome were treated with bisphosphonates and all five developed hypocalcaemia, compared to one of the five who received conventional treatment (P = 0.047). CONCLUSION: Milk-alkali was the third leading cause of hypercalcaemia of any degree and the second cause of severe hypercalcaemia among inpatients without ESRD. In milk-alkali syndrome, treatment with bisphosphonates contributes to post-treatment hypocalcaemia.


Asunto(s)
Hipercalcemia/complicaciones , Hipercalcemia/etiología , Enfermedades Renales/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Carbonato de Calcio/efectos adversos , Difosfonatos/efectos adversos , Difosfonatos/uso terapéutico , Diuréticos/uso terapéutico , Femenino , Humanos , Hipercalcemia/sangre , Hipercalcemia/diagnóstico , Hipercalcemia/tratamiento farmacológico , Enfermedades Renales/sangre , Enfermedades Renales/tratamiento farmacológico , Magnesio/sangre , Masculino , Persona de Mediana Edad , Potasio/sangre , Estudios Retrospectivos , Distribución por Sexo , Bicarbonato de Sodio/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA